Sera Prognostics (SERA) Income from Continuing Operations (2020 - 2026)
Sera Prognostics (SERA) posted Income from Continuing Operations of 10858000.0 for Q1 2026, down 117.33% on a QoQ basis from 4996000.0 in Q4 2025, and down 27.82% year-over-year from 15042190.15 in Q1 2025.
Sera Prognostics (SERA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Sera Prognostics' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 10858000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 27.82% year-over-year to 10858000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 40888000.0 (down 17.14% YoY) and the FY2025 annual result came in at 117951000.0, down 5.32% from the prior year.
- Income from Continuing Operations was 10858000.0 for Q1 2026 at Sera Prognostics, down from 4996000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 4996000.0 in Q4 2025 and bottomed at 12653000.0 in Q3 2025.
- A 5-year average of 9932705.88 and a median of 10436000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 70.51% — and 2025, when it surged 46.7%.
- Sera Prognostics' Income from Continuing Operations stood at 10436000.0 in 2022, then increased by 28.09% to 7505000.0 in 2023, then declined by 24.9% to 9374000.0 in 2024, then jumped by 46.7% to 4996000.0 in 2025, then sank by 117.33% to 10858000.0 in 2026.
- Business Quant data shows SERA's Income from Continuing Operations at 10858000.0 in Q1 2026, 4996000.0 in Q4 2025, and 12653000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.81 Bn | 175.52 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.98 Bn | 126.10 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 108.67 Bn | 99.45 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 68.36 Bn | 66.91 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 47.70 Bn | 44.03 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 28.67 Bn | 27.55 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 28.55 Bn | 26.27 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.97 Bn | 26.40 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.33 Bn | 2.07 Bn | 273.95 Mn |
| 10 | Sera Prognostics | 107.55 Mn | 107.55 Mn | -28,000.00 | -10.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.86 Mn |
| Dec 31, 2025 | -5.00 Mn |
| Sep 30, 2025 | -12.65 Mn |
| Jun 30, 2025 | -12.38 Mn |
| Mar 31, 2025 | -8.50 Mn |
| Dec 31, 2024 | -9.37 Mn |
| Sep 30, 2024 | -8.29 Mn |
| Jun 30, 2024 | -8.74 Mn |
| Mar 31, 2024 | -8.92 Mn |
| Dec 31, 2023 | -7.51 Mn |
| Sep 30, 2023 | -7.83 Mn |
| Jun 30, 2023 | -11.47 Mn |
| Mar 31, 2023 | -11.35 Mn |
| Dec 31, 2022 | -10.44 Mn |
| Sep 30, 2022 | -11.21 Mn |
| Jun 30, 2022 | -11.90 Mn |
| Mar 31, 2022 | -12.45 Mn |
| Dec 31, 2021 | -12.55 Mn |
| Sep 30, 2021 | -9.88 Mn |
| Jun 30, 2021 | -7.36 Mn |